Q66.80 — Congenital vertical talus deformity, unspecified foot
ICD-10-CM
Prior Authorization
No Prior Auth Required
Code is covered without prior authorization (high confidence)
Documentation Required
- Chronic sialorrhea — documentation member is refractory to pharmacotherapy (e.g., anticholinergics).
- Anal fissures — documentation of failure to first-line therapy such as topical calcium channel blockers or topical nitrates.
- Hirschsprung disease with internal sphincter achalasia — documentation that treatment is after endorectal pull-through and refractory to laxative therapy.
- Services are covered 'if selection criteria are met' — documentation should demonstrate that the applicable selection criteria (as referenced in the policy) are met for the specific product and indication.
Key Coverage Criteria
- OnabotulinumtoxinA (Botox) medically necessary indications (initial approval): Achalasia — Treatment of achalasia when the member has tried and failed or is a poor candidate for conventional therapy such as pneumatic dilation and surgical myotomy.
- Botulinum toxin type A has become 1st-line therapy for Frey's syndrome.
- Botulinum toxin type A therapy for blepharospasm
- Botulinum toxin for chronic low back pain
- Botulinum toxin for Raynaud's phenomenon / ischemic digits
- Botulinum toxin for temporomandibular disorders
2 Active Policies
AETNA-CPB-0113 — Botulinum Toxin
AETNA-CPB-0669 — Subtalar Implant for Foot Deformity
Related Codes
Have a follow-up question?
Ask Verity about documentation requirements, denial risks, or coverage in your state.